Literature DB >> 3460984

Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.

T Kalager, A Digranes, T Bergan, T Rolstad.   

Abstract

Using an agar well diffusion assay, the concentrations of ofloxacin were measured in serum and skin blister fluid after an oral dose of 300 mg given with or without a standardized meal. The apparent lag time was longer when the drug was taken with food than in the fasting state and the serum peak concentrations occurred later; the rates of absorption being 1.72 +/- 1.12/h (S.D.) and 3.40 +/- 1.56/h respectively. The mean peak concentrations of each individual in serum and blister fluid were 3.8 +/- 1.6 mg/l and 1.7 +/- 0.5 mg/l, respectively, when the drug was taken with food, compared with 4.2 +/- 1.9 mg/l and 2.1 +/- 0.7 mg/l in the fasting state. The rate of penetration into blister fluid was not influenced by the intake of food. The elimination half-life was 9.0 +/- 6.2 h in serum and 13.5 +/- 7.8 h in blister fluid when the volunteers were fasting. The corresponding values in the non-fasting state were 6.3 +/- 5.5 h and 10.6 +/- 4.6 h. The ratio of the area under the concentration versus time curve (AUC0-infinity) for blister fluid and serum was 1.20 +/- 0.70 when ofloxacin was given without food and 1.03 +/- 0.34 when given with the meal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460984     DOI: 10.1093/jac/17.6.795

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  The effect of food or milk on the absorption kinetics of ofloxacin.

Authors:  M N Dudley; C R Marchbanks; S C Flor; B Beals
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Effect of food on absorption of lomefloxacin.

Authors:  W D Hooper; R G Dickinson; M J Eadie
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Effect of food on enoxacin absorption.

Authors:  A A Somogyi; F Bochner; J A Keal; P E Rolan; M Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.

Authors:  R Farinotti; J H Trouvin; V Bocquet; N Vermerie; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 7.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 8.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

9.  Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers.

Authors:  R Warlich; H C Korting; M Schäfer-Korting; E Mutschler
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

10.  Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis.

Authors:  J M Block; R A Walstad; A Bjertnaes; P E Hafstad; M Holte; I Ottemo; P L Svarva; T Rolstad; L E Peterson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.